reports
Pagseguro Digital Ltd: 1 director
A director at Pagseguro Digital Ltd bought 498,500 shares at 9.965USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
- Jonathan Moreland
- Jonathan Moreland
HTGC HERCULES CAPITAL INC.
FMNB FARMERS NATIONAL BANC CORP.
GAM GENERAL AMERICAN INVESTORS CO. INC.
WVE WAVE LIFE SCIENCES
TSI TCW STRATEGIC INCOME FUND INC.
STIM STIMSONITE CORP
GO GROCERY OUTLET HOLDING
AHCO ADAPTHEALTH
GTLB GITLAB INC
TSM TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
MXF THE MEXICO FUND
GF INC.
AFCG THE NEW GERMANY FUND
VERO INC.
AFC GAMMA
INC.
VENUS CONCEPT INC
- Jonathan Moreland
PANW PALO ALTO NETWORKS INC.
OSUR ORASURE TECHNOLOGIES INC.
FMNB FARMERS NATIONAL BANC CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
LULU LULULEMON ATHLETICA INC
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
CRT CROSS TIMBERS ROYALTY TRUST
KYN KAYNE ANDERSON MLP INVESTMENT CO.
INSE INSPIRED ENTERTAINMENT
NEPH NEPHROS INC
NEXT NEXTDECADE
AXR AMREP
KOD KODIAK SCIENCES
NMM NAVIOS MARITIME PARTNERS
REEMF RARE ELEMENT RESOURCES
RPAY REPAY HOLDINGS (A)
AHCO ADAPTHEALTH
ADV ADVANTAGE SOLUTIONS INC (A)
PX P10 INC
AIRS AIRSCULPT TECHNOLOGIES INC
BORR BORR DRILLING LTD
TPST MILLENDO THERAPEUTICS
KMPH INC.
IAUX KEMPHARM INC
SBSW I-80 GOLD CORP.
MNR SIBANYE-STILLWATER LTD
TLPH MACH NATURAL RESOURCES LP
MXF TALPHERA INC.
IBIO THE MEXICO FUND
GF INC.
AFCG IBIO INC.
FMBM THE NEW GERMANY FUND
GSM INC.
AFC GAMMA
INC.
F & M BANK CORP
GLOBE SPECIALTY METALS INC.
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Offic...
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A. Munsie as Chief Legal Officer. “Jeff brings deep life sciences experience across critical stages of growth, from preclinical through commercialization,” sai...
- Jonathan Moreland
WAT WATERS CORPORATION
VNO VORNADO REALTY TRUST
TGL. TECNOGLASS INC.
SCM STELLUS CAPITAL INVESTMENT CORP
ROCK GIBRALTAR INDUSTRIES INC.
POOL POOL CORPORATION
OSUR ORASURE TECHNOLOGIES INC.
NSP INSPERITY INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
NFBK NORTHFIELD BANCORP INC.
MTN VAIL RESORTS INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CRM SALESFORCE.COM INC.
BBSI BARRETT BUSINESS SERVICES INC.
WD WALKER & DUNLOP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
PLBC PLUMAS BANCORP
BWFG BANKWELL FINANCIAL GROUP
SVRA SAVARA
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
ULBI ULTRALIFE
SONO SONOS
EML THE EASTERN COMPANY
STIM STIMSONITE CORP
BLDR BUILDERS FIRSTSOURCE
AEYE INC.
PHR AUDIOEYE INC
AHCO PHREESIA
AVO ADAPTHEALTH
AMR MISSION PRODUCE
TRIN ALPHA METALLURGICAL RESOURCES INC
AIRS TRINITY CAPITAL INC
EXFY AIRSCULPT TECHNOLOGIES INC
SBSW EXPENSIFY INC
VANI SIBANYE-STILLWATER LTD
GRNT VIVANI MEDICAL INC
NBBK GRANITE RIDGE RESOURCES INC
SDHC NB BANCORP INC.
MXF SMITH DOUGLAS HOMES CORP
SNES THE MEXICO FUND
GF INC.
AFCG SENESTECH INC.
SI THE NEW GERMANY FUND
SENS INC.
AFC GAMMA
INC.
SHOULDER INNOVATIONS INC
SENSEONICS HOLDINGS INC.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing ...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on March 16, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 27,920 shares and an inducement re...
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results a...
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update – Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldostero...
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrosta...
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results – The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in adults with hypertension – – Topline results from the Phase 2 Explore-OSA exploratory trial did not reduce AHI; demonstrated a clinically meaningful reduction in blood pressure and favorable safety and tolerability in this population with d...
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 F...
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2025, after the fina...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing ...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 23, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 27,920 shares and...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing ...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering 33,504 shares and in...
Mineralys Therapeutics Provides Corporate Update and Announces Partici...
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones. In...
- Jonathan Moreland
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recog...
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup – Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors – RADNOR, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and...
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing R...
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on November 24, 2025, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 146,000 shares of ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.